PE20090315A1 - Composiciones de fenilalanina amoniaco liasa procariotica y metodos para usar composiciones de la misma - Google Patents

Composiciones de fenilalanina amoniaco liasa procariotica y metodos para usar composiciones de la misma

Info

Publication number
PE20090315A1
PE20090315A1 PE2008000889A PE2008000889A PE20090315A1 PE 20090315 A1 PE20090315 A1 PE 20090315A1 PE 2008000889 A PE2008000889 A PE 2008000889A PE 2008000889 A PE2008000889 A PE 2008000889A PE 20090315 A1 PE20090315 A1 PE 20090315A1
Authority
PE
Peru
Prior art keywords
compositions
variant
liasa
ammonia
phenylalanine
Prior art date
Application number
PE2008000889A
Other languages
English (en)
Spanish (es)
Inventor
Michel Claude Vellard
Paul Andrew Fitzpatrick
Emil D Kakkis
Daniel J Wendt
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39868905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090315(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of PE20090315A1 publication Critical patent/PE20090315A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2008000889A 2007-05-25 2008-05-23 Composiciones de fenilalanina amoniaco liasa procariotica y metodos para usar composiciones de la misma PE20090315A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/807,227 US7534595B2 (en) 2006-06-12 2007-05-25 Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof

Publications (1)

Publication Number Publication Date
PE20090315A1 true PE20090315A1 (es) 2009-03-19

Family

ID=39868905

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000889A PE20090315A1 (es) 2007-05-25 2008-05-23 Composiciones de fenilalanina amoniaco liasa procariotica y metodos para usar composiciones de la misma

Country Status (29)

Country Link
US (1) US7534595B2 (enExample)
EP (2) EP2152868B1 (enExample)
JP (1) JP5670183B2 (enExample)
KR (2) KR101603796B1 (enExample)
CN (1) CN101842482B (enExample)
AR (2) AR066716A1 (enExample)
AU (1) AU2008263190B2 (enExample)
BR (1) BRPI0811267B8 (enExample)
CA (1) CA2687450C (enExample)
CL (1) CL2008001497A1 (enExample)
CY (2) CY1116894T1 (enExample)
DK (1) DK2152868T3 (enExample)
EA (1) EA018443B1 (enExample)
ES (1) ES2551315T3 (enExample)
HR (1) HRP20151268T1 (enExample)
HU (2) HUE025784T2 (enExample)
IL (1) IL202132A (enExample)
LT (1) LTC2152868I2 (enExample)
LU (1) LUC00133I2 (enExample)
MX (1) MX2009012453A (enExample)
MY (1) MY151413A (enExample)
NL (1) NL301011I2 (enExample)
NO (1) NO2019037I1 (enExample)
PE (1) PE20090315A1 (enExample)
PL (1) PL2152868T3 (enExample)
PT (1) PT2152868E (enExample)
SI (1) SI2152868T1 (enExample)
TW (1) TWI418633B (enExample)
WO (1) WO2008153776A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7537923B2 (en) * 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
WO2010014225A2 (en) * 2008-07-30 2010-02-04 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
EP4062928A3 (en) 2010-02-04 2022-11-30 BioMarin Pharmaceutical Inc. Prokaryotic phenylalanine ammonia-lyases and their use for treating phenylketonuria and hyperphenylalaninemia
EP3222288A1 (en) * 2012-07-27 2017-09-27 University of North Texas Genetically modified probiotic for the treatment of phenylketonuria (pku) disease
PL2986722T3 (pl) 2013-04-18 2019-10-31 Codexis Inc Skonstruowane polipeptydy amoniakoliazy fenyloalaniny
BR112016011195A2 (pt) 2013-11-18 2017-09-19 Rubius Therapeutics Inc Células eritroides enucleadas e seus métodos de fabricação, composição farmacêutica e seu uso, uso de uma população de células eritroides, biorreator, mistura de células e dispositivo médico
CN106456744A (zh) 2014-04-01 2017-02-22 鲁比厄斯治疗法股份有限公司 用于免疫调节的方法和组合物
EP3145536B1 (en) 2014-04-16 2021-10-27 Codexis, Inc. Engineered tyrosine ammonia lyase
CA2970638A1 (en) 2014-12-22 2016-06-30 Codexis, Inc. Human alpha-galactosidase variants
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法(一)
JP6994018B2 (ja) 2016-07-26 2022-01-14 バイオマリン ファーマシューティカル インコーポレイテッド 新規アデノ随伴ウイルスキャプシドタンパク質
CN109844127B (zh) * 2016-08-30 2023-09-19 三菱化学株式会社 突变型酶的制造方法及突变型醇酰基转移酶
CN106497905A (zh) * 2016-12-14 2017-03-15 江南大学 一株鱼腥藻来源的苯丙氨酸脱氨酶的突变体
AU2018217495B2 (en) * 2017-02-13 2021-03-04 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
CN107653275A (zh) * 2017-10-30 2018-02-02 安徽工程大学 D‑苯丙氨酸的制备方法
CN108004225B (zh) * 2017-12-19 2020-05-08 江南大学 一种成团泛菌来源的苯丙氨酸氨基变位酶的突变体
KR20210008501A (ko) 2018-05-09 2021-01-22 바이오마린 파머수티컬 인크. 페닐케톤뇨증을 치료하는 방법
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
EP3807409A4 (en) 2018-06-12 2022-08-03 Codexis, Inc. Engineered tyrosine ammonia lyase
EP3820833A4 (en) * 2018-07-12 2022-08-03 Codexis, Inc. MODIFIED AMMONIA-LYASE PHENYLALANINE POLYPEPTIDES
AU2019397401A1 (en) 2018-12-14 2021-06-17 Codexis, Inc. Engineered tyrosine ammonia lyase
MY207075A (en) 2018-12-20 2025-01-28 Codexis Inc Human alpha-galactosidase variants
CN110456056A (zh) * 2019-07-22 2019-11-15 浙江大学 一种新生儿苯丙酮尿症无创筛查试纸的制备方法
BR112022003705A2 (pt) 2019-08-30 2022-05-24 Codexis Inc Lipase recombinante, composição, sequência de polinucleotídeo recombinante, vetor de expressão, composição farmacêutica para o tratamento de insuficiência pancreática, célula hospedeira, métodos para produzir uma lipase recombinante e para tratar e/ou prevenir os sintomas de insuficiência pancreática, e, uso
MX2022007399A (es) 2019-12-20 2022-09-19 Codexis Inc Variantes de alfa-glucosidasa ácida diseñadas.
EP4103711A4 (en) 2020-02-04 2024-02-28 Codexis, Inc. Engineered leucine decarboxylases
WO2021168060A1 (en) * 2020-02-19 2021-08-26 Trustees Of Tufts College Methods for engineering amino acid ammonia lyase enzymes and enzymes thereby obtained
TW202144575A (zh) 2020-04-03 2021-12-01 美商拜奧馬林製藥公司 使用aav及治療調配物之苯酮尿症治療
JP2023539634A (ja) 2020-08-28 2023-09-15 コデクシス, インコーポレイテッド 操作されたアミラーゼバリアント
AU2021334371A1 (en) 2020-08-28 2023-03-09 Codexis, Inc. Engineered protease variants
WO2022245924A1 (en) * 2021-05-19 2022-11-24 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects
AU2022279241A1 (en) 2021-05-21 2023-11-30 Syntis Bio, Inc. Engineered methionine gamma lyase variants
WO2023044381A1 (en) * 2021-09-16 2023-03-23 Arcturus Therapeutics, Inc. Compositions and methods for treating phenylketonuria
JP2024540358A (ja) 2021-11-01 2024-10-31 シンティス バイオ,インコーポレイティド 工学操作ロイシン脱炭酸酵素
CN117417925A (zh) * 2022-07-18 2024-01-19 浙江泽科塔生物医药有限公司 Pal变体、包含该pal变体的药物组合物以及用于制备该pal变体的方法
CN118931888A (zh) * 2023-05-09 2024-11-12 重庆派金生物科技有限公司 苯丙氨酸裂解酶突变体及其偶联物或其药学上可接受的盐
GB202307239D0 (en) 2023-05-15 2023-06-28 Evox Therapeutics Ltd Gene therapies for Phenylketonuria
CN116478975B (zh) * 2023-06-16 2023-09-01 苏州优信合生技术有限公司 高活性苯丙氨酸解氨酶突变体及其表达菌株
WO2025106759A1 (en) 2023-11-17 2025-05-22 Biomarin Pharmaceutical Inc. Conjugates of phenylalanine ammonia-lyase and poegma and methods for their use

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252822A (en) 1979-12-26 1981-02-24 Children's Hospital Medical Center Method for treating phenylketonuria
US4562151A (en) 1983-09-06 1985-12-31 Monsanto Company Stabilization of L-phenylalanine ammonia-lyase enzyme
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
WO1994013817A1 (en) 1992-12-04 1994-06-23 Me Medical Enzymes Ag Genetically engineered glutaminase and its use in antiviral and anticancer therapy
JP2930723B2 (ja) 1992-11-19 1999-08-03 アンティキャンサー インコーポレーテド 抗メチオニン化学療法における抗腫瘍薬としてのメチオニナーゼの使用
DK75593D0 (enExample) 1993-06-25 1993-06-25 Novo Nordisk As
JPH09510352A (ja) * 1994-03-15 1997-10-21 プリズム ファーマシューティカルズ,インコーポレイティド 遺伝子療法及び前部の眼疾患のためのヘパリン結合成長因子
ATE455171T1 (de) 1995-09-21 2010-01-15 Genentech Inc Varianten des menschlichen wachstumshormons
CU22585A1 (es) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune.
US6548644B1 (en) 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US5981239A (en) 1997-09-24 1999-11-09 Great Lakes Chemical Corp. Synthesis of optically active phenylalanine analogs using Rhodotorula graminis
US7026446B1 (en) * 1997-12-24 2006-04-11 Diatech Pty Ltd. Bifunctional molecules
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6461849B1 (en) 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6403312B1 (en) 1998-10-16 2002-06-11 Xencor Protein design automatic for protein libraries
US6686164B1 (en) 1998-10-30 2004-02-03 Novozymes A/S Low allergenic protein variants
CA2328614C (en) 1999-02-12 2012-06-26 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
WO2001041782A2 (en) * 1999-12-09 2001-06-14 Chiron Corporation Method for administering a cytokine to the central nervous system and the lymphatic system
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
EP1280924A2 (en) 2000-04-14 2003-02-05 University of South Carolina Research Foundation Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses
US6967097B2 (en) 2000-07-24 2005-11-22 Pcbu Services, Inc. Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same
EP1309705B1 (en) * 2000-07-25 2012-02-15 Immunomedics Inc. Multivalent target binding protein
WO2002026028A2 (en) * 2000-09-26 2002-04-04 The Regents Of The University Of California Characterization of phenylalanine ammonia-lyase (pal) gene in wounded lettuce
WO2002038609A2 (en) * 2000-11-10 2002-05-16 Proteopharma Aps Apolipoprotein conjugates
JP4722396B2 (ja) 2002-02-26 2011-07-13 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 遺伝要素の組換え方法
AU2003246690B2 (en) * 2002-07-17 2010-03-11 Cytos Biotechnology Ag Molecular antigen arrays using a virus like particle derived from the AP205 coat protein
JP2006516095A (ja) 2002-11-14 2006-06-22 ザ スクリップス リサーチ インスティテュート 脂肪酸アミドヒドロラーゼ(faah)の結晶形
AU2004247737B2 (en) * 2003-06-11 2009-04-23 Wyeth Platelet glycoprotein IB alpha variant fusion polypeptides and methods of use thereof
FR2868318B1 (fr) * 2004-04-01 2012-11-16 Commissariat Energie Atomique Antigene tat stabilise et ses applications pour la vaccination anti-vih
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
AU2005286763A1 (en) 2004-09-17 2006-03-30 Biomarin Pharmaceutical, Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
EP1869174B1 (en) 2005-03-10 2015-02-18 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
WO2008069958A2 (en) 2006-12-01 2008-06-12 The Salk Institute For Biological Studies Substrate switched ammonia lyases and mutases
US7537923B2 (en) 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof

Also Published As

Publication number Publication date
LTC2152868I2 (lt) 2020-09-25
EP2657335A1 (en) 2013-10-30
AU2008263190A1 (en) 2008-12-18
CN101842482A (zh) 2010-09-22
SI2152868T1 (sl) 2015-12-31
PL2152868T3 (pl) 2016-01-29
US20080008695A1 (en) 2008-01-10
LUC00133I1 (enExample) 2019-10-16
LTPA2019517I1 (lt) 2019-10-25
CA2687450A1 (en) 2008-12-18
KR101603796B1 (ko) 2016-03-17
MY151413A (en) 2014-05-30
KR20100024437A (ko) 2010-03-05
DK2152868T3 (en) 2015-11-16
LUC00133I2 (enExample) 2020-07-16
WO2008153776A1 (en) 2008-12-18
AU2008263190B2 (en) 2014-04-17
JP2010529835A (ja) 2010-09-02
ES2551315T3 (es) 2015-11-18
HUS1900049I1 (hu) 2019-11-28
EP2152868A1 (en) 2010-02-17
CN101842482B (zh) 2014-10-22
WO2008153776A8 (en) 2009-07-30
US7534595B2 (en) 2009-05-19
CY2019039I1 (el) 2020-05-29
PT2152868E (pt) 2015-11-13
AR110834A2 (es) 2019-05-08
BRPI0811267B1 (pt) 2020-11-10
JP5670183B2 (ja) 2015-02-18
AR066716A1 (es) 2009-09-09
CL2008001497A1 (es) 2009-01-09
IL202132A0 (en) 2010-06-16
CY1116894T1 (el) 2017-04-05
NL301011I2 (nl) 2020-05-13
EP2152868B1 (en) 2015-09-02
TWI418633B (zh) 2013-12-11
HUE025784T2 (en) 2016-05-30
TW200902052A (en) 2009-01-16
CA2687450C (en) 2019-03-26
MX2009012453A (es) 2010-01-25
HK1135141A1 (zh) 2010-05-28
HRP20151268T1 (hr) 2015-12-18
IL202132A (en) 2017-06-29
CY2019039I2 (el) 2020-05-29
EA200970980A1 (ru) 2010-04-30
NL301011I1 (nl) 2019-10-16
EA018443B1 (ru) 2013-08-30
BRPI0811267B8 (pt) 2021-05-25
BRPI0811267A2 (pt) 2014-10-07
KR20150038753A (ko) 2015-04-08
NO2019037I1 (no) 2019-10-16

Similar Documents

Publication Publication Date Title
PE20090605A1 (es) Composiciones de fenilalanina amoniaco-liasa procariotica y metodos del tratamiento del cancer usando composiciones de la misma
AR050030A1 (es) Composiciones blanqueadoras dentales y sistemas para su administracion
UA100840C2 (ru) Композиция для лечения вирусного гепатита
WO2006136607A3 (de) Verwendung von hydrophobin-polypeptiden sowie konjugaten aus hydrophobin-polypeptiden mit wirk- oder effektstoffen und ihre herstellung sowie deren einsatz in der kosmetik
AR110834A2 (es) MOLÉCULA DE UNA VARIANTE AISLADA DE FENILALANINA AMONIACOLIASA DE ANABAENA VARIABILIS (AvPal)
NZ592705A (en) 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
WO2006091780A3 (en) Nanoparticulate formulations of docetaxel and analogues thereof
MX2010004571A (es) Composiciones y metodos que comprenden peptidos y proteasas de aminoacidos basicos.
BRPI0513310A (pt) análogos de tetrapeptìdeo
SG179414A1 (en) Macrocyclic hepatitis c serine protease inhibitors
CY1115413T1 (el) Ανασυνδυασμενη fsh η οποια περιλαμβανει αλφα 2,3- και αλφα 2',6-sialylation
AR050717A1 (es) Composiciones farmaceuticas
MX2011012015A (es) Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
NZ707160A (en) A stable aqueous composition comprising human insulin or an analogue or derivative thereof
PH12012501522A1 (en) Oral care compositions
PH12012501620A1 (en) Oral care compositions
TNSN07477A1 (en) Use of sanglifehrin in hcv
AR079750A2 (es) Comprimidos bucodispersables y metodo de fabricacion
CO6382109A2 (es) Formulación de depósito de octreotida con niveles de exposición constantemente altos
MY160372A (en) Composition for improving brain function and method for improving brain function
CL2007003190A1 (es) Compuestos derivados de arilsulfonil-pirrolidinas; procedimiento de obtencion; composicion farmaceutica; y uso en la prevencion o tratamiento de enfermedades tales como psicosis, depresion, alzheimer, entre otras.
BRPI0719885B8 (pt) peptídeos peguilados como moduladores de receptores de pth, seus usos, e composição.
AR064269A1 (es) Formulaciones inhalantes de bisfosfonato y metodos para su utilizacion
ATE503491T1 (de) Verbesserte anthraximpfstoffe und abgabeverfahren
TW200716088A (en) Formulations and methods for treating amyloidosis

Legal Events

Date Code Title Description
FG Grant, registration